Evicenter
P&T meetings

Bezuclastinib

Gastrointestinal stromal tumor

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted April 2026
Last updated
76 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Gastrointestinal stromal tumor

Economic burden and healthcare resource utilization

4 evidence topics · 4 sources

GIST recurrence costs

“The total healthcare cost was significantly higher for patients with GIST recurrence, with a difference of $4464 per patient per month (p < 0.01).” (opens the source at this quote in a new tab)

Hospital utilization

“The study analyzed 48,690 hospitalizations” (opens the source at this quote in a new tab)

“with a primary diagnosis of GIST between 2016 and 2020.” (opens the source at this quote in a new tab)

Mutation testing and subsequent treatment

“Dropout to/for further lines of treatment was 15% for patients with a Tested mutation vs. 47% in Untested patients.” (opens the source at this quote in a new tab)

U.S. inpatient burden

“In 2009, there were 14,562 hospitalizations among patients with GISTs at a rate of 44/100,000 admissions.” (opens the source at this quote in a new tab)